Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06173128 · ClinicalTrials.gov registry record
Respiratory Microbiota and Immune Response in CVID
A clinical trial of CVID, sponsored by Boston University.
- Completed
- Registry status
- 75
- Enrollment target
- 1
- Study location
NCT06173128 is a study of CVID that has completed, run by Boston University. The registered enrollment target is 75 participants. The trial reports 1 study location across 1 state.
The verdict
NCT06173128, a study of CVID, has completed, sponsored by Boston University.
- COMPLETED
- Registry status
- 75 participants
- Enrollment target
- 1
- Study location
Study Summary
Common variable immunodeficiency (CVID) is the most prevalent symptomatic primary immunodeficiency. Respiratory ailments are the most frequent complications of CVID, with chronic pulmonary disease developing in 30-60% and even more experiencing frequent acute respiratory infections. This project aims to establish cutting-edge approaches to study pulmonary biology in CVID and apply novel bioinformatics strategies to study complex interactions among microbes and host cells by direct sampling of the respiratory tract. The central hypothesis for this research is that antibody (Ab) deficiency in CVID alters respiratory microbiota and host interactions to drive pulmonary disease.
Conditions Studied
Study Locations (1)
Massachusetts
- Boston Medical Center - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 75 participants |
| Start Date | 2024-03-15 |
| Est. Completion | 2026-02-15 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06173128
The ClinicalTrials.gov registry entry for NCT06173128 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 75 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boston University, which has 185 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with CVID appearing as the primary indexed condition, and to 0 interventions.
NCT06173128 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT06173128 about?
NCT06173128 is a clinical study titled "Respiratory Microbiota and Immune Response in CVID". Common variable immunodeficiency (CVID) is the most prevalent symptomatic primary immunodeficiency. Respiratory ailments are the most frequent complications of CVID, with chronic pulmonary disease developing in 30-60% and even more experiencing frequent acute respiratory infections. This project aim...
What is the current status of trial NCT06173128?
This trial is currently completed. The enrollment target is 75 participants. The study started on 2024-03-15. Estimated completion is 2026-02-15.
What conditions does trial NCT06173128 study?
This clinical trial studies the following conditions: CVID.
Who is sponsoring clinical trial NCT06173128?
This trial is sponsored by Boston University, which has 185 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06173128 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for CVID
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.